Highest-materiality recent filing
Petros Pharmaceuticals grants 7M restricted shares to Chairman, two directors, and President
Aggregate 7,000,000 restricted shares granted to Joshua Silverman (Chairman), Bruce Bernstein, Fady Boctor, and Wayne Walker.
Petros Pharmaceuticals grants 7.25M RSUs to executives and directors; 50% vested immediately
Joshua Silverman (Chairman) receives 4,375,000 RSUs; Bruce Bernstein 1,875,000; Fady Boctor 500,000; Wayne Walker 500,000.
Nasdaq notifies Petros Pharmaceuticals of common stock delisting effective Nov 7, 2025
Nasdaq notified Petros on Nov 3, 2025, of intention to delist common stock on Nov 7, 2025.
Petros Pharmaceuticals assigns subsidiary assets (Metuchen, Timm, Pos-T-Vac) to creditor trust
Effective June 16, 2025, Petros assigned all assets of subsidiaries Metuchen, Timm Medical, and Pos-T-Vac to a third-party fiduciary for benefit of creditors.
Petros Pharma receives Nasdaq delisting notice; trading to move to OTC Markets
Delisting due to failing minimum equity, bid price ($1.00), and public interest concerns from Feb 2025 offering.
Nasdaq notified Petros on April 28 of public interest concerns regarding its February 19, 2025 public offering as a new delisting basis under Rule 5810(d).
Nasdaq notified Petros on Apr 8 it fails $2.5M minimum stockholders' equity requirement, adding to existing bid price deficiency.
Company terminated Marcum LLP as auditor on April 5, 2025, and engaged CBIZ CPAs P.C. as new independent auditor for FY 2025.
Petros Pharmaceuticals Prices $9.6 Million Public Offering of Common Stock and Warrants
Petros Pharmaceuticals entered securities purchase agreement for 13,950,012 units and 26,049,988 pre-funded units at $0.24 and $0.2399 per unit.
Extended maturity date of Series A Convertible Preferred Stock from prior date to February 15, 2025.
Metuchen failed to pay installment due Oct 1, 2024; all obligations accelerated.
Petros Pharma stockholders OK reverse stock split up to 1:25
Directors Silverman, Bernstein, Walker elected to one-year terms.
Petros Pharmaceuticals dismisses EisnerAmper as auditor, appoints Marcum; cites material weaknesses
Audit committee dismissed EisnerAmper as independent auditor on January 8, 2024; engaged Marcum effective immediately.
Petros Pharmaceuticals raises $15M via private placement to advance OTC STENDRA
Issued 15,000 Series A Convertible Preferred shares (stated value $1,000 each) and warrants for up to 6,666,668 common shares at $2.25.
Petros Pharma Q3 net sales negative $1.4M, net loss $13.8M on excessive returns
Net sales of -$1.4M vs $2.1M YoY; Prescription Medicines segment net sales -$2.1M due to expired product returns.
Petros Pharmaceuticals reports Q2 net sales of $4.2M, first positive adjusted EBITDA of $0.2M
Q2 net sales of $4.2M, up 68% from $2.5M in Q2 2021; net loss narrowed to $1.8M from $2.1M.
Petros Pharmaceuticals denies fraudulent acquisition press release; reports to Nasdaq
A press release issued July 28, 2022 claiming an acquisition of Petros was fraudulent and not authorized by the company.
Petros Pharmaceuticals receives Nasdaq deficiency notice for bid price below $1.00
Received Nasdaq letter on June 22, 2022 for bid price <$1.00 over 30 consecutive business days ended June 21, 2022.
Petros Pharma reports 2021 net sales $7.8M, net loss down 56% to $9.0M
Net sales $7.8M vs $9.6M in 2020; prescription sales fell to $4.6M due to competitive coupons.
Petros Pharmaceuticals signs manufacturing agreement with Thermo Fisher's Patheon for Stendra
Metuchen (Petros subsidiary) and Patheon (Thermo Fisher) will collaborate on tech transfer and validation to manufacture Stendra at Patheon's Cincinnati facility.
Petros Pharmaceuticals raises $7.5M in registered direct offering and private placement
Sold 2,186,589 shares at $3.43 each to accredited investors, including largest shareholder.
Petros Pharmaceuticals raises $10M in registered direct offering and private placement
Gross proceeds of $10M from sale of 3,333,333 shares at $3.00/share; net proceeds ~$9.3M.
Petros Pharma Q3 net sales fall 37% to $2.2M; net loss narrows to $1.7M
Net sales $2.2M, down from $3.5M YoY; Prescription Medicines net sales declined 47% due to higher allowances and returns.
Petros Pharmaceuticals raises ~$5.7M in registered direct offering led by largest shareholder
Offering of 3,323,616 shares at $1.715 per share; warrants for same number at same price, 5-year term.
On June 18, 2026, the board of directors (the “Board”) of the Company appointed Robert Weinstein to the positions of Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer of the Company, effective immediately.
On June 18, 2026, Petros Pharmaceuticals, Inc. (the “Company”) and Mitchell Arnold, who served as the Company’s Vice President of Finance, Principal Accounting Officer and Principal Financial Officer, mutually agreed to the separation of Mr. Arnold from such roles, effective as of June 18, 2026
On October 1, 2024, John Shulman, who served as a member of the board of directors (the “Board”) of Petros Pharmaceuticals, Inc. (the “Company”), tendered his resignation from his role as director of the Company, effective as of October 1, 2024.
On October 2, 2024, Greg Bradley, who served as a member of the Board tendered his resignation from his role as director of the Company, effective as of October 2, 2024.
On February 28, 2022 (the “Termination Date”), Andrew Gesek resigned from his position as President of Timm Medical Technologies, Inc., a wholly-owned subsidiary of Petros Pharmaceuticals, Inc. (the “Company”), effective immediately.
Max materiality 0.90 · Median 0.60 · Most common event other_material